Stoke Therapeutics STOK Insider Ownership

Updated Oct 11, 2026

Across the past 12 months, open-market trades by Stoke Therapeutics insiders were all sales, totaling $8.94 million (280.55K shares).

• A count shows 8 insiders selling STOK stock on the open market over the past 12 months and none buying.
• Adrian R. Krainer (Director) led open-market sales of Stoke Therapeutics stock over the past 12 months with $3.9 million (121.42K shares), most recently on March 10, 2026.
• The latest open-market trade on record is a sale of 627 shares for $16,509 by Jonathan Allan (General Counsel & Corporate Secretary) on October 2, 2026.
• In transactions other than open-market trades, Stoke Therapeutics insiders acquired 251.19K shares through option exercises and conversions over the past 12 months.
• According to Business Quant data, insiders at Stoke Therapeutics reported 4.41Mn shares in total in their latest Form 4 filings, or 6.68% of the 66.02Mn shares outstanding; that total is up 0.01% from 4.41Mn shares at the end of Q2 2026.
• Stoke Therapeutics insiders hold 503.54K shares directly (11.42% of their total) and 3.91Mn shares (88.58%) indirectly, through entities such as trusts and partnerships.
• Per Business Quant, 9 insiders of STOK hold shares, counting officers, directors and 10% owners who have filed a Form 4 in the past two years.
• STOK's largest insider holders by reported holdings are Skorpios Trust (10% owner, 3.91Mn shares), Adrian R. Krainer (Director, 283.3K shares) and Edward M. Kaye (Director, 124.56K shares).
• The holding of Skorpios Trust makes up 88.58% of all shares held by Stoke Therapeutics insiders.
• Over the trailing 12 months, 15 insiders reported transactions in STOK stock across 55 Form 4 filings.
• The insider holdings and trades above for Stoke Therapeutics reflect Form 4 filings through October 2, 2026.